U.S. Markets open in 1 hr 34 mins

Arcadia Biosciences, Inc. (RKDA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.5600+0.1000 (+4.07%)
At close: 4:00PM EDT

2.5700 +0.01 (0.39%)
Pre-Market: 7:36AM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.4600
Open2.4300
Bid0.0000 x 2200
Ask2.5800 x 800
Day's Range2.3700 - 2.5600
52 Week Range2.2600 - 6.4000
Volume651,231
Avg. Volume3,205,043
Market Cap54.621M
Beta (5Y Monthly)-0.73
PE Ratio (TTM)N/A
EPS (TTM)-0.4670
Earnings DateMay 11, 2021 - May 17, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.45
  • Arcadia Biosciences (RKDA) Acquires European Food Ingredient Platform that Further Enhances its GoodWheat™ Business
    PR Newswire

    Arcadia Biosciences (RKDA) Acquires European Food Ingredient Platform that Further Enhances its GoodWheat™ Business

    Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a leader in science-based approaches to enhancing the quality and nutritional value of crops and food ingredients, today announced it has acquired, through Arcadia SPA, S.L., the assets of Agrasys S.A, a food ingredients company based in Barcelona, Spain. The transaction includes the physical and intellectual property assets to enable Arcadia to commercialize Tritordeum, a proprietary cereal grain that was developed at the Instituto de Agricultura Sostenible - Consejo Superior de Investigaciones Científicas, (IAS-CSIC) the largest public institution dedicated to agricultural research in Spain, and subsequently licensed exclusively to Agrasys for commercialization.

  • RKDA: Arcadia Biosciences is Well Funded for Management’s 2021 Growth Initiatives in GoodWheat & GoodHemp; Also a Review of 2020 Achievements
    Zacks Small Cap Research

    RKDA: Arcadia Biosciences is Well Funded for Management’s 2021 Growth Initiatives in GoodWheat & GoodHemp; Also a Review of 2020 Achievements

    By Steven Ralston, CFA NASDAQ:RKDA READ THE FULL RKDA RESEARCH REPORT Arcadia Biosciences (NASDAQ:RKDA) is on the cusp of meaningful revenue growth, primarily from management’s initiative into the hemp space, but also from the restructured strategic relationship with Bioceres Crop Solutions for the commercialization of HB4 soybean technology in the Central and South America. Furthermore, the

  • SmarterAnalyst

    Wednesday’s Pre-Market: Here’s What You Need To Know Before The Market Opens

    U.S. futures were trading relatively flat on Wednesday as investors wait for further details regarding the US stimulus program. Dow and S&P futures were up around 0.1% while the Nasdaq futures were trading around 0.3% higher at the time of writing. Investors are waiting for earnings results from Walgreens Boots (WBA), Acuity Brands (AYI) and Unifirst (UNF) before the bell, while Micron (MU), Ncino (NCNO) and Verint (VRNT) are expected to report after the market closes. Arcadia Biosciences (RKDA) was both the most actively traded stock and the biggest pre-market gainer after reporting record revenues that increased six-fold compared to the prior year. RKDA was trading 46% higher at the time of writing with ClearOne (CLRO) and ProPhase Labs (PRPH) climbing 36% and 22%, respectively. VirTra (VTSI) was the weakest share in the pre-market falling 25%, followed by 9 Meters Biopharma (NMTR) and Asia Pac Wire &Cable (APWC), which were down 22% and 18%, respectively. In corporate earnings news, Shares of Chewy (CHWY) were up almost 10% in pre-market trading after the company reported better-than-expected Q4 results. Revenues of $2.04 billion grew 51% year-over-year and beat consensus estimates of $1.96 billion while gross margins expanded 190 basis points to 25.5% and the adjusted EBITDA margin improved 290 basis points to 1.2%. Meanwhile, BlackBerry (BB) fell 5.5% before the bell after reporting Q4 results that missed analysts’ expectations. Earnings of $0.03 per share declined 66.7% year-over-year and were in-line with the Street’s estimates. However, lower top-line revenues and a contraction in gross and operating margins led to the earnings decline. Adjusted revenues of $215 million fell 26.1% year-over-year while adjusted software and services revenue declined 13.7% year-over-year. Equilium (EQ) rose 7% before the open after announcing positive data from its Phase 1 EQUALISE study evaluating Itolizumab in patients with systemic lupus erythematosus (SLE). “These initial data from the EQUALISE study demonstrate a favourable safety and tolerability profile for subcutaneous delivery of itolizumab in SLE patients, with the most frequent adverse events being mild to moderate injection site reactions,” said Equillium’s Chief Medical Officer, Dolca Thomas. In M&A news, DraftKings (DKNG) announced the acquisition of Vegas Sports Information Network, Inc. (VSiN) for an undisclosed fee. VSiN has an established infrastructure that DraftKings can immediately help expand to grow its audience alongside the expansion of legal sports betting in the US. DraftKings is live with mobile and/or retail sports betting in 14 states and VSiN has delivered trusted sports betting news, analysis, and data to US sports bettors since 2017. Bioventus (BVS) has acquired Bioness Inc. for a total consideration of $110 million. CEO, Ken Reali, said, “We aim to accelerate Bioness’ revenue growth by leveraging our existing global network of approximately 300 sales representatives calling on orthopaedic, pain and podiatric physicians as well as expanding market access and reimbursement processing capabilities.” Bioventus expects this acquisition to be revenue accretive and boost its multi-year revenue growth. More recent articles from Smarter Analyst: HyreCar’s 4Q Revenues Jump 42%; Street Sees 85% Upside SOC Telemed Slips On Wider-Than-Expected 4Q Loss DraftKings Snaps Up VSiN To Boost Content For Customers; Shares Pop 5% Chewy’s 4Q Revenues Outshine Estimates; Stock Pops Over 10%